ENElliott B. Nickbarg

Elliott B. Nickbarg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elliott B. Nickbarg has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Chad Chamberlin

    Quantitative Biosciences

    4 shared publications
  • Peter Saradjian

    Quantitative BiosciencesDepartments of , Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

    3 shared publications
  • Alan Hruza

    Discovery Chemistry

    2 shared publications
  • Christine Andrews

    Quantitative BiosciencesDepartments of , Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

    2 shared publications
  • David Jonathan Bennett

    Discovery ChemistryDepartments of , Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

    2 shared publications
  • Hua Zhou

    Discovery ChemistryDepartments of , Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

    2 shared publications

Latest Publications

  • The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors

    by Ken Ellsworth, Peter Nizner, Anthony Ogawa, Alan Hruza, Lan Wei, Dexi Yang, Matthew Lombardo, Lisa Sonatore, Christopher M. Barbieri, Alexandra Wickham, et al.

    Despite advances in anticoagulant drug discovery to establish a new standard of care, represented by Factor Xa (FXa) inhibitors, additional therapies are needed to address the concomitant bleeding risk posed by these agents. Factor XI (FXI) plays a key role in the intrinsic coagulation cascade contributing to thrombin generation and fibril formation, and there is an increasing weight of evidence supporting a comparable efficacy and superior safety profile of FXI-based oral anticoagulants. A novel allosteric mechanism of action (MoA) for inhibiting FXI activation to Factor XIa (FXIa) was discovered by applying an AS-MS-based screen to the FXI zymogen. Biochemical and biophysical characterization of these structurally diverse small-molecule classes confirmed this mode of inhibition as specific to the FXI zymogen, and a high-resolution FXI-inhibitor cocomplex structure identified the binding pocket that is distal to the FXI cleavage site. These FXI Activation Inhibitors were active in translational functional assays, prolonging activated partial thromboplastin time (aPTT) in human plasma and demonstrating dose-dependent antithrombotic effects in the rabbit arteriovenous-shunt model of thrombosis. The results affirm that FXI Activation Inhibitors are a novel mechanism for the potential treatment of thrombotic disorders.


  • Open Access

    Targeting RNA with small molecules: lessons learned from Xist RNA

    by Elliott B. Nickbarg, Kerrie B. Spencer, Jonathan David Mortison, Jeannie T. Lee

    Although more than 98% of the human genome is noncoding, nearly all drugs on the market target one of about 700 disease-related proteins. However, an increasing number of diseases are now being attributed to noncoding RNA and the ability to target them would vastly expand the chemical space for drug development. We recently devised a screening strategy based upon affinity-selection mass spectrometry and succeeded in identifying bioactive compounds for the noncoding RNA prototype, Xist. One such compound, termed X1, has drug-like properties and binds specifically to the RepA motif of Xist in vitro and in vivo. Small-angle X-ray scattering analysis reveals that X1 changes the conformation of RepA in solution, thereby explaining the displacement of cognate interacting protein factors (PRC2 and SPEN) and inhibition of X-chromosome inactivation. In this Perspective, we discuss lessons learned from these proof-of-concept experiments and suggest that RNA can be systematically targeted by drug-like compounds to disrupt RNA structure and function.


  • Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors

    by Derun Li, Yongqi Deng, Abdelghani Achab, Indu Bharathan, Brett Andrew Hopkins, Wensheng Yu, Hongjun Zhang, Sulagna Sanyal, Qinglin Pu, Hua Zhou, et al.

    Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as an attractive target for cancer immunotherapy. An automated ligand identification system screen afforded the tetrahydroquinoline class of novel IDO1 inhibitors. Potency and pharmacokinetic (PK) were key issues with this class of compounds. Structure-based drug design and strategic incorporation of polarity enabled the rapid improvement on potency, solubility, and oxidative metabolic stability. Metabolite identification studies revealed that amide hydrolysis in the D-pocket was the key clearance mechanism for this class. Strategic survey of amide isosteres revealed that carbamates and N-pyrimidines, which maintained exquisite potencies, mitigated the amide hydrolysis issue and led to an improved rat PK profile. The lead compound 28 is a potent IDO1 inhibitor, with clean off-target profiles and the potential for quaque die dosing in humans.


  • Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)

    by Catherine White, Meredeth A. McGowan, Hua Zhou, Nunzio Sciammetta, Xavier Fradera, Jongwon Lim, Elizabeth M. Joshi, Christine Andrews, Elliott B. Nickbarg, Phillip Cowley, et al.

    Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune evasion and poor prognosis for patients. In particular, IDO1 inhibition is of interest as a combination therapy with immune checkpoint inhibition. Through an Automated Ligand Identification System (ALIS) screen, a diamide class of compounds was identified as a promising lead for the inhibition of IDO1. While hit 1 possessed attractive cell-based potency, it suffered from a significant right-shift in a whole blood assay, poor solubility, and poor pharmacokinetic properties. Through a physicochemical property-based approach, including a focus on lowering AlogP98 via the strategic introduction of polar substitution, compound 13 was identified bearing a pyridyl oxetane core. Compound 13 demonstrated improved whole blood potency and solubility, and an improved pharmacokinetic profile resulting in a low predicted human dose.


  • Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry

    by Noreen F. Rizvi, John A. Howe, Ali Nahvi, Daniel J. Klein, Thierry O. Fischmann, Hai-Young Kim, Mark A. McCoy, Scott S. Walker, Alan Hruza, Matthew P. Richards, et al.

    Recent advances in understanding the relevance of non-coding RNA (ncRNA) to disease have increased interest in drugging ncRNA with small molecules. The recent discovery of ribocil, a structurally distinct synthetic mimic of the natural ligand of the flavin mononucleotide (FMN) riboswitch, has revealed the potential chemical diversity of small molecules that target ncRNA. Affinity-selection mass spectrometry (AS-MS) is theoretically applicable to high-throughput screening (HTS) of small molecules binding to ncRNA. Here we report the first application of the Automated Ligand Detection System (ALIS), an indirect AS-MS technique, for the selective detection of small molecule-ncRNA interactions, high-throughput screening against large unbiased small-molecule libraries, and identification and characterization of novel compounds (structurally distinct from both FMN and ribocil) that target the FMN riboswitch. Crystal structures reveal different compounds induce various conformations of the FMN riboswitch, leading to different activity profiles. Our findings validate the ALIS platform for HTS screening for RNA-binding small molecules, and further demonstrate that ncRNA can be broadly targeted by chemically diverse yet selective small molecules as therapeutics.


  • Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase

    by Jr. John P. Santa Maria, Yumi Park, Lihu Yang, Nicholas Murgolo, Michael D. Altman, Paul Zuck, Greg Adam, Chad Chamberlin, Peter Saradjian, Peter Dandliker, et al.

    Though phenotypic and target-based high-throughput screening approaches have been employed to discover new antibiotics, the identification of promising therapeutic candidates remains challenging. Each approach provides different information, and understanding their results can provide hypotheses for a mechanism of action (MoA) and reveal actionable chemical matter. Here, we describe a framework for identifying efficacy targets of bioactive compounds. High throughput biophysical profiling against a broad range of targets coupled with machine learning was employed to identify chemical features with predicted efficacy targets for a given phenotypic screen. We validate the approach on data from a set of 55 000 compounds in 24 historical internal antibacterial phenotypic screens and 636 bacterial targets screened in high-throughput biophysical binding assays. Models were built to reveal the relationships between phenotype, target, and chemotype, which recapitulated mechanisms for known antibacterials. We also prospectively identified novel inhibitors of dihydrofolate reductase with nanomolar antibacterial efficacy against Mycobacterium tuberculosis. Molecular modeling provided structural insight into target–ligand interactions underlying selective killing activity toward mycobacteria over human cells.


  • Mass Spectrometry‐Based Screening and Characterization of Protein–Ligand Complexes in Drug Discovery

    by Christine L. Andrews, Michael R. Ziebell, Elliott Nickbarg, Xianshu Yang